Healthy bodies, healthy lives

What's New

More

RSS

2015.07.29
Finances
PDF/562KB
Presentation Material (First Quarter Financial Results for FY2015)
2015.07.29
Finances
PDF/309KB
Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2016
2015.07.29
Finances
PDF/152KB
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2016[Japanese GAAP](Unaudited)
2015.07.24
R&D
PDF/223KB
Sumitomo Dainippon Pharma, CiRA and Hitachi Start Joint Research on Development of Key Evaluation Technologies: Evaluation for Industrialization in the Field of Regenerative Medicine --- Toward Application of Human iPS Cell for Parkinson’s Disease Treatment ---
2015.07.15
Licensing
PDF/122KB
Sumitomo Dainippon Pharma Announces Commercialization Partnership with Servier on Its Atypical Antipsychotic Agent Latuda (lurasidone hydrochloride) for Australia
2015.07.09
Licensing
PDF/66KB
Eli Lilly Japan and Sumitomo Dainippon Pharma signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist “Trulicity Subcutaneous Injection 0.75 mg Ateos”